The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
The effect of erythropoietin on normal and neoplastic cells
|
|---|---|
| Published in |
Biologics: Targets & Therapy, June 2012
|
| DOI | 10.2147/btt.s32281 |
| Pubmed ID | |
| Authors |
Steve Elliott, Angus M Sinclair |
| Abstract |
Erythropoietin (Epo) is an essential hormone that binds and activates the Epo receptor (EpoR) resident on the surface of erythroid progenitor cells, thereby promoting erythropoiesis. Recombinant human erythropoietin has been used successfully for over 20 years to treat anemia in millions of patients. In addition to erythropoiesis, Epo has also been reported to have other effects, such as tissue protection and promotion of tumor cell growth or survival. This became of significant concern in 2003, when some clinical trials in cancer patients reported increased tumor progression and worse survival outcomes in patients treated with erythropoiesis-stimulating agents (ESAs). One of the potential mechanisms proffered to explain the observed safety issues was that functional EpoR was expressed in tumors and/or endothelial cells, and that ESAs directly stimulated tumor growth and/or antagonized tumor ablative therapies. Since then, numerous groups have performed further research evaluating this potential mechanism with conflicting data and conclusions. Here, we review the biology of endogenous Epo and EpoR expression and function in erythropoiesis, and evaluate the evidence pertaining to the expression of EpoR on normal nonhematopoietic and tumor cells. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Uruguay | 1 | 1% |
| Unknown | 83 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 18% |
| Student > Bachelor | 13 | 15% |
| Student > Master | 12 | 14% |
| Researcher | 9 | 11% |
| Other | 7 | 8% |
| Other | 9 | 11% |
| Unknown | 19 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 24% |
| Agricultural and Biological Sciences | 17 | 20% |
| Biochemistry, Genetics and Molecular Biology | 15 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Nursing and Health Professions | 1 | 1% |
| Other | 4 | 5% |
| Unknown | 24 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 July 2016.
All research outputs
#7,430,186
of 25,584,565 outputs
Outputs from Biologics: Targets & Therapy
#93
of 274 outputs
Outputs of similar age
#50,062
of 179,466 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 9 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,466 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.